Table 1 Baseline characteristics of patients with statin use and matched controls
From: Association of statin use and increase in lipoprotein(a): a real-world database research
Characteristic | Item | Non-statin use (n = 21,083) | Statin use (n = 21,083) |
|---|---|---|---|
Age |  < 45 | 2345(11.12%) | 2345(11.12%) |
|  | 46–65 | 9947(47.18%) | 9947(47.18%) |
|  |  > 65 | 8791(41.70%) | 8791(41.70%) |
Sex | Male | 11,026(52.30%) | 11,019(52.26%) |
| Â | Female | 10,057(47.70%) | 10,064(47.74%) |
Comorbidity history* | Non-Comorbidity (FE)# | 16,778(79.58%) | 16,747(79.43%) |
| Â | Comorbidity (FE) | 4305(20.42%) | 4336(20.57%) |
Follow-up time | [0.5–3) years | 15,385(72.97%) | 15,374(72.92%) |
|  | [3–5) years | 4154(19.70%) | 4160(19.73%) |
|  |  ≥ 5 years | 1544(7.32%) | 1549(7.35%) |
Laboratory results | Lp(a)$ at FT (Mean, CI95%, mg/L) | 7.99(4.07, 9.92) | 7.98(3.88, 9.91) |
| Â | LDL-C (Mean, CI95%, mmol/L) | 3.00(1.90, 4.63) | 3.04(1.89, 4.91) |
| Â | HDL-C (Mean, CI95%, mmol/L) | 1.30(0.74, 2.08) | 1.30(0.76, 2.10) |
| Â | APO-A (Mean, CI95%, mmol/L) | 1.33(0.83, 1.93) | 1.33(0.86, 1.94) |
| Â | APO-B (Mean, CI95%, mmol/L) | 0.99(0.58, 1.56) | 0.99(0.58, 1.63) |
| Â | TC (Mean, CI95%, mmol/L) | 5.06(3.41, 7.11) | 5.11(3.43, 7.51) |
| Â | TG (Mean, CI95%, mmol/L) | 1.63(0.58, 4.38) | 1.68(0.60, 4.81) |
| Â | CRP (Mean, CI95%, mmol/L) | 14.01(0.21, 85.20) | 13.35(0.22, 76.50) |